NCT04477876 (NKCD160MEL) is a clinical trial in Melanoma, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT04477876?

NCT04477876 is sponsored by Assistance Publique - Hôpitaux de Paris.

Is NCT04477876 still recruiting?

NCT04477876 is currently not yet recruiting. Last updated 20 July 2020.

Last reviewed 2020-07-20 · How we verify

NCT04477876: NKCD160MEL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?

Not yet recruiting Last updated 20 July 2020

What this trial tests

trial in Melanoma in 55 participants. Not yet recruiting.

Timeline

1 September 2020

Primary endpoint
15 December 2027

15 December 2027

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	55
Start date	1 September 2020
Primary completion	15 December 2027
Estimated completion	15 December 2027

Conditions studied

Melanoma — all drugs for Melanoma →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Although immunotherapy revolutionized melanoma outcomes over the last 10 years, only 40-50% of patients respond to treatments and 25% develop acquired resistances. Natural Killer (NK) cells naturally recognize and kill tumor cells. However, the immunosuppressive micro-environment generated by the tumor decreases NK cells' killing activity. CD160 is a NK cell receptor identified and characterized in our laboratory. Engagement of the GPI isoform (CD160-GPI) initiates NK cell cytotoxic response. Upon NK cell activation, a transmembrane isoform (CD160-TM) is neo-synthesized which promotes the amplification of activated NK cell cytotoxicity. The aim of this study is to assess the phenotypic profile of advanced stages melanoma patients' NK cells (mainly CD160-TM expression or its induction) and therefore the therapeutic potential of the use of an anti-CD160-TM agonist antibody to boost the NK-dependent mechanism leading to tumor depletion.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment.
Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, et al · · 2023 · cited 58× · PMID 37345056 · DOI 10.3390/cancers15102718
Tumor necrosis factor superfamily signaling: life and death in cancer.
Ababneh O, Nishizaki D, Kato S, Kurzrock R. · · 2024 · cited 18× · PMID 39363128 · DOI 10.1007/s10555-024-10206-6
Role of Natural Killer Cells in Uveal Melanoma.
Javed A, Milhem M. · · 2020 · cited 16× · PMID 33317028 · DOI 10.3390/cancers12123694
A Systematic Review of the Advances in the Study of T Lymphocyte Suppressor Receptors in HBV Infection: Potential Therapeutic Targets.
Zhou D, Liu L, Liu J, Li H, et al · · 2024 · cited 1× · PMID 38592036 · DOI 10.3390/jcm13051210

Verify or expand the search:

Other recruiting trials for Melanoma

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04477876 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 20 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04477876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing